Synapse - Hematologic Malignancies, Division of

With up to 8 years of therapy, asciminib (ASC) monotherapy demonstrated continued favorable efficacy, safety, and tolerability in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) without the T315I mutation: Final results from the phase 1 x2101 study

Meeting Abstract

Hochhaus, A.; Kim, D. W.; Cortes, J.; Sasaki, K.; Mauro, M.; Hughes, T. P.; Breccia, M.; Talpaz, M.; Minami, H.; Goh, Y. T.; more...
Blood (2023)

Fulltext@MSK | Save

Asciminib (ASC) in combination with Imatinib (IMA), nilotinib (NIL), or dasatinib (DAS) may be a potential treatment (Tx) option in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase or accelerated phase (Ph + CML-CP/AP): Final results from the asciminib phase 1 study

Meeting Abstract

Cortes, J.; Lang, F.; Rea, D.; Hochhaus, A.; Breccia, M.; Goh, Y. T.; Heinrich, M. C.; Hughes, T. P.; Janssen, J. J. W. M.; le Coutre, P.; more...
Blood (2023)

Fulltext@MSK | Save

Impact of mutations in blood cancer-related genes on clinical outcomes in chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 tyrosine kinase inhibitors ( TKIs) in the Ascembl trial

Meeting Abstract

Branford, S.; Hochhaus, A.; Mauro, M.; Minami, Y.; Rea, D.; Freitas, Cmbd; Serrano-Fernandez, P.; Obourn, V.; Bruederle, A.; Espurz, N.; more...
Blood (2023)

Fulltext@MSK | Save

Estimated savings after stopping tyrosine kinase inhibitor treatment among patients with chronic myeloid leukemia

Journal Article

Winn, A. N.; Atallah, E.; Cortes, J.; Deininger, M. W. N.; Kota, V.; Larson, R. A.; Moore, J. O.; Mauro, M. J.; Oehler, V. G.; Pinilla-Ibarz, J.; more...
JAMA Network Open (2023)

Fulltext@MSK | Save

ASC2ESCALATE: A US, phase II open-label, single-arm, dose-escalation study of asciminib monotherapy in second-line (2L) and first-line (1L) treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP)

Meeting Abstract

Atallah, E.; Mauro, M.; Sasaki, K.; Levy, M.; Koller, P.; Yang, D.; Laine, D.; Sabo, J.; Gu, E. N.; Cortes, J.
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

Responses with asciminib continue to deepen over time in patients with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs) in the phase III ASCEMBL study

Meeting Abstract

Mauro, M.; Hochhaus, A.; Hughes, T.; Rea, D.; Boquimpani, C.; Minami, Y.; Apperley, J.; Garcia-Gutiérrez, V.; Kapoor, S.; Espurz, N.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save